Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

AGP ups Sensus Healthcare PT to $7.50 from $2.95

Alliance Global Partners raised its price target for Sensus Healthcare (NASDAQ:SRTS) to $7.50 from $2.95, citing fourth quarter results that were well ahead of consensus estimates. The stock closed at $4.94 on March 1...

March 2, 2021

Markets

Stifel starts coverage on 10 rare disease-focused companies

Stifel began coverage on 10 rare disease-focused companies, with seven “buy” and three “hold” ratings, noting that with an estimated 7,000-plus rare diseases – 95% of which lack approved therapy – these are early...

March 1, 2021

Markets

Cantor starts DarioHealth at OW; PT $35

Cantor Fitzgerald launched coverage of DarioHealth (NASDAQ:DRIO) with an “overweight” rating and price target of $35. The stock closed at $29.16 on Feb. 24. Dario is a digital health company that is developing and...

February 25, 2021

Markets

SVB Leerink starts Lensar at OP; PT $20

SVB Leerink initiated coverage of Lensar (NASDAQ:LNSR) with an “outperform” rating and price target of $20. The stock closed at $9.50 on Feb. 23. Lensar was recently spun out from PDL Biopharma and is, “in our view, an...

February 24, 2021

Markets

Cowen ups TransMedics PT to $44 from $20

Cowen raised its price target for TransMedics (NASDAQ:TMDX) to $44 from $20, citing multiple catalysts ahead for all three of the company’s organ programs. The stock closed at $23.82 on Feb. 23. TransMedics has...

February 24, 2021

Markets

Raymond James starts Skylight Health Group at OP 2; PT $2.25 (Canadian)

Raymond James initiated coverage of Skylight Health Group (TSXV:SHG) with an “outperform (2)” ranting and $2.25 (Canadian) target price. The stock closed at $1.66 on Feb. 23. Skylight operates a large and growing U.S...

February 24, 2021

Markets

BTIG ups MannKind PT to $8 from $4

BTIG raised its price target for MannKind (NASDAQ:MNKD) to $8 from $4, citing a recent meeting with MannKind CEO, Michael Castagna, to hear an extensive discussion on Technosphere and Tyvaso DPI expansion, among other...

February 24, 2021

Markets

WB starts Taysha Gene Therapies at OP; fair value estimate $46

William Blair launched coverage of Taysha Gene Therapies (NASDAQ:TSHA) with an “outperform” rating and fair value estimate of $46. The stock closed at $26.66 on Feb. 23. Taysha is focused on developing and...

February 23, 2021

Markets

Cantor cuts Otonomy PT to $6 from $13

Cantor Fitzgerald slashed its price target for Otonomy (NASDAQ:OTIC) to $6 from $13 but maintained its “overweight” rating, after the company announced that the Phase 3 study of OTIVIDEX in Ménière’s disease did not...

February 22, 2021

Markets

Cantor ups Evolus PT to $20 from $11

Cantor Fitzgerald raised its price target for Evolus (NASDAQ:EOLS) to $20 from $11, following a litigation settlement, which Cantor believes “increases earnings visibility for Evolus, and removes a large overhang on the...

February 22, 2021

Markets

AGP starts ReShape Lifesciences at buy; PT $12

Alliance Global Partners initiated coverage of ReShape Lifesciences (OTCQB:RSLS) with a “buy” rating and price target of $12. The stock was quoted at $7.54 in afternoon trading on Feb. 18. ReShape is a rare pure-play in...

February 18, 2021

Markets

AGP ups Obalon Therapeutics to buy; PT $6.15 from 75 cents

Alliance Global Partners upgraded Obalon Therapeutics (NASDAQ:OBLN) to “buy” and raised its price target to $6.15 from 75 cents, reflecting a new valuation of ReShape Lifesciences, Obalon’s merger partner. Shares of...

February 18, 2021

Markets

Maxim ups Titan Pharma to buy from hold; PT $11

Maxim Group upgraded Titan Pharmaceuticals (NASDAQ:TTNP) to “buy” from “hold” with a new price target of $11, citing multiple strategy, management, cap-structure and financing changes at Titan, which should position the...

February 18, 2021

Markets

Hepion Pharma closes $88.4-million offering

Hepion Pharmaceuticals (NASDAQ:HEPA) closed a public offering of 44.2 million common shares at a price of $2 each for gross proceeds of $88.4-million. After deducting underwriting fees and other offering expenses, net...

February 18, 2021

Markets

SVB Leerink starts Amryt Pharma at OP; PT $40

SVB Leerink launched coverage of Amryt Pharma (NASDAQ:AMYT) with an “outperform” rating and $40 price target. The stock closed at $14.15 on Feb. 12. “Filsuvez is poised to be the first approved treatment for...

February 16, 2021

Markets

HCW starts Plus Therapeutics at buy; PT $7

H.C. Wainwright launched coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and $7 price target. The stock closed at $3.75 on Feb. 10. Plus is focused on developing novel therapies against brain cancer. The...

February 11, 2021

Markets

Maxim starts TRACON Pharma at buy; PT $24

Maxim Group initiated coverage of TRACON Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $24 price target. The stock closed at $9.91 on Feb. 9. TRACON is developing a differentiated anti-PD-L1 checkpoint...

February 10, 2021

Markets

Maxim ups Cyclo Therapeutics PT to $25 from $12

Maxim Group more than doubled its price target for Cyclo Therapeutics (NASDAQ:CYTH) to $25 from $12, citing updates from the Phase 1 and Phase 1/2 clinical programs for Trapsol Cyclo (TC) in Neimann-Pick Type C (NPC)...

February 9, 2021

Markets

SVB Leerink starts Eledon Pharma at OP; PT $34

SVB Leerink launched coverage of Eledon Pharmaceuticals (NASDAQ:ELDN) with an “outperform” rating and a $34 price target. The stock closed at $14.99 on Feb. 5. Eledon is developing AT-1501, a potentially best-in-class...

February 8, 2021

Markets

Maxim ups Lineage PT to $5 from $3

Maxim Group raised its price target for Lineage Cell Therapeutics (NYSE American:LCTX) to $5 from $3, citing an agreement with Neurgain Technologies to develop a novel parenchymal delivery injection (PDI) system for...

February 8, 2021

Markets

Maxim ups BrainStorm Cell Therapeutics to buy from hold; PT $12

Maxim Group upgraded BrainStorm Cell Therapeutics (NASDAQ:BCLI) to “buy” from “hold” with a price target of $12, citing a pullback in the stock since the ALS Phase 3 results in the fourth quarter of 2020, opportunities...

February 4, 2021

Markets

HCW ups Ocugen to buy from neutral; PT $4.50

H.C. Wainwright upgraded Ocugen (NASDAQ:OCGN) to “buy” from “neutral” with a price target of $4.50, citing a definitive agreement with Bharat Biotech to co-develop, supply, and commercialize Bharat’s COVID-19 vaccine...

February 4, 2021

Subscribe